AnaptysBio, Inc. - ANAB STOCK NEWS

AnaptysBio (Nasdaq: ANAB) announced the appointment of Daniel Faga as interim CEO following the resignation of Hamza Suria. Faga, who has extensive experience in the biopharmaceutical industry, aims to advance the company's three clinical-stage antibody programs. AnaptysBio is conducting a strategic portfolio review while focusing on ongoing clinical trials for its lead candidates, including imsidolimab, rosnilimab, and ANB032. The company reported having approximately $615 million in cash as of the end of 2021, which will support its development activities.

AnaptysBio announced the results of the ACORN Phase 2 trial for imsidolimab in moderate-to-severe acne, revealing no significant improvement over placebo in primary and secondary endpoints. Consequently, the company will discontinue imsidolimab's clinical development for acne. However, imsidolimab showed safety and efficacy in previous trials for generalized pustular psoriasis (GPP), with ongoing enrollment in the GEMINI-1 Phase 3 trial. AnaptysBio maintains a solid financial position, ending 2021 with approximately $615 million in cash and an anticipated 2022 net cash burn between $90-$100 million.

On March 7, 2022, AnaptysBio reported its Q4 and FY 2021 results, highlighting a net loss of $32.5 million for Q4 and $57.8 million for the year. The company's cash and equivalents increased to $615.2 million, primarily due to a $250 million royalty monetization transaction with Sagard Healthcare Royalty Partners. Key pipeline updates include the initiation of the Phase 3 GEMINI-1 trial for imsidolimab in generalized pustular psoriasis, and anticipation of top-line results from multiple clinical trials in 2022, including imsidolimab for acne and hidradenitis suppurativa.

AnaptysBio, a clinical-stage biotechnology company (Nasdaq: ANAB), announced that CEO Hamza Suria will present at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, from 8:15 to 8:55 a.m. ET. This event focuses on the company’s innovative antibody product candidates addressing inflammation and immuno-oncology.

The presentation can be accessed via a live audio webcast on the J.P. Morgan website or AnaptysBio's investor section, with a replay available for 30 days post-conference.

On November 29, 2021, AnaptysBio, a clinical-stage biotechnology firm, appointed Daniel Faga to its Board of Directors. Faga brings over 20 years of experience in corporate strategy and finance within the biopharmaceutical sector. CEO Hamza Suria highlighted Faga's strategic vision as a valuable asset for the company's advancement of its therapeutic antibody programs. Faga expressed enthusiasm about AnaptysBio's potential and its robust, innovative pipeline targeting inflammation and immuno-oncology.

SAN DIEGO, Nov. 15, 2021 – AnaptysBio, a clinical-stage biotechnology firm listed on Nasdaq under the symbol ANAB, announced that CEO Hamza Suria will present an overview of the company at the 2021 Jefferies London Healthcare Conference on November 18 at 3:00 a.m. ET. The presentation can be accessed online and will also be available for 30 days following the event. The company specializes in first-in-class antibody product candidates aimed at addressing inflammation and immuno-oncology.

AnaptysBio announced positive results from a Phase 1 trial of its anti-PD-1 agonist antibody, rosnilimab, demonstrating favorable safety and pharmacokinetics. The trial involved 144 healthy volunteers, showcasing a robust pharmacodynamic profile with a dose-dependent reduction of PD-1+ T cells. The findings support the planned AZURE Phase 2 trial for moderate-to-severe alopecia areata patients, highlighting a promising pathway for treating T-cell driven inflammatory diseases. Rosnilimab exhibited a favorable tolerability profile, suggesting strong potential for broader clinical application.

AnaptysBio (Nasdaq: ANAB) disclosed its Q3 2021 results, highlighting collaboration revenue of $20.9 million, primarily from JEMPERLI approvals. The company anticipates ending 2021 with approximately $600 million in cash post a significant $250 million royalty monetization deal with Sagard Healthcare. Imsidolimab's Phase 3 trials for GPP have commenced, showing promising efficacy with 75% of patients achieving primary endpoints. However, research and development expenses rose to $22.2 million, indicating ongoing investment in clinical programs amidst a net loss of $6.7 million.

AnaptysBio has entered a deal with Sagard Healthcare Royalty Partners, receiving a $250 million upfront payment while granting Sagard an 8% royalty on JEMPERLI sales below $1 billion. Sagard could earn up to $105 million in milestones and will receive royalties of 12-25% on sales above $1 billion. The agreement aims to enhance AnaptysBio's funding for its antibody programs and has capped returns for Sagard at up to 165% by 2027. Analysts predict peak annual sales for JEMPERLI could reach $1.4-$2.8 billion, indicating strong market potential.